Ian Taylor Sells 9,020 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $17.08 on Thursday. Arvinas, Inc. has a twelve month low of $16.07 and a twelve month high of $51.51. The firm has a market cap of $1.17 billion, a PE ratio of -6.16 and a beta of 1.88. The business has a fifty day moving average of $18.38 and a 200-day moving average of $22.76.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the firm earned ($2.53) earnings per share. On average, analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on ARVN. Guggenheim reiterated a “buy” rating and set a $57.00 price objective on shares of Arvinas in a research note on Wednesday, February 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. Oppenheimer increased their price objective on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Stifel Nicolaus dropped their price objective on Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price objective (down from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, Arvinas currently has a consensus rating of “Buy” and a consensus price target of $60.00.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARVN. GF Fund Management CO. LTD. acquired a new stake in Arvinas in the fourth quarter worth about $28,000. KBC Group NV increased its position in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after purchasing an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after purchasing an additional 440 shares during the period. Quantbot Technologies LP increased its position in Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after purchasing an additional 2,601 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in Arvinas in the fourth quarter worth about $171,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.